CERO · CIK 0001870404
CERO THERAPEUTICS HOLDINGS, INC.
Annual figures as reported, FY2021–FY2025. Ratios and growth rates derived on-page.
Biological Products, (No Diagnostic Substances)
Company profile
Net income
−$19.9M
▼ −173.3% vs FY2023
Operating cash flow
−$16.1M
▼ −956.7% vs FY2023
Diluted EPS
−$1248.64
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersNet income — Mar ’26 quarter
−$5.9M
▼ −15.3% vs Mar ’25
Diluted EPS — trailing 12 months
−$1248.64
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Mar ’26 | — | — | — | −$5.9M | — | −$0.20 |
| Dec ’25 | — | — | — | −$4.5M | — | — |
| Sep ’25 | — | — | — | −$4.9M | — | −$9.10 |
| Jun ’25 | — | — | — | −$5.4M | — | −$61.71 |
| Mar ’25 | — | — | — | −$5.1M | — | −$31.82 |
| Sep ’24 | — | — | — | −$4.2M | — | −$170.22 |
| Jun ’24 | — | — | — | −$2.4M | — | −$302.32 |
| Dec ’23 | — | — | — | −$1.4M | — | −$1247.99 |
Profitability & returns
quality of earningsReturns on capital
Net income vs year-end equity and assets
Cash flow
cash generationOperating cash flow
Net cash from operations
Shareholder returns
capital allocationCapital returned
Cash paid out as dividends and share repurchases
Dividends paidBuybacks
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Key ratios
derived per fiscal year| Fiscal year | ROA | Current ratio | DPS |
|---|---|---|---|
| FY2025 | −547.1% | 0.30× | $10.37 |
| FY2024 | — | 0.50× | — |
| FY2023 | −142.2% | 0.56× | — |
| FY2022 | −1.6% | 1.38× | — |
| FY2021 | — | 13.88× | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | — | — | — | −$19.9M | — | −$16.1M | — | $3.6M | $9.1M | −$5.4M | $1.7M | — |
| FY2024 | — | — | — | — | — | — | — | $6.2M | $8.1M | −$2.3M | $3.3M | — |
| FY2023 | — | — | −$7.7M | −$7.3M | −$1248.64 | −$1.5M | — | $5.1M | $5.1M | −$42.1M | $97K | — |
| FY2022 | — | — | −$2.9M | −$668K | — | −$1.1M | — | $42.4M | $39.9M | −$11.0M | $476K | — |
| FY2021 | — | — | — | — | — | — | — | $180.1M | $9.2M | $0 | $0 | — |
Latest filings
the most recent regulatory filings424B3PROSPECTUS SUPPLEMENT2026-06-26 ↗8-KCURRENT REPORT2026-06-26 ↗424B3PROSPECTUS SUPPLEMENT2026-05-29 ↗8-KCURRENT REPORT2026-05-29 ↗424B3PROSPECTUS SUPPLEMENT2026-05-15 ↗10-QQUARTERLY REPORT2026-05-15 ↗424B3PROSPECTUS SUPPLEMENT2026-05-01 ↗8-KCURRENT REPORT2026-05-01 ↗424B3PROSPECTUS SUPPLEMENT2026-05-01 ↗10-K/AAMENDMENT NO. 1 TO FORM 10-K2026-04-30 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.